Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01829295 · ClinicalTrials.gov registry record · Phase 3
Methotrexate and Mycophenolate Mofetil for UVEITIS
A Phase 3 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 3
- Development phase
- 216
- Enrollment target
NCT01829295 is a Phase 3 study that has completed, run by University of California, San Francisco. The registered enrollment target is 216 participants.
The verdict
NCT01829295, a Phase 3 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 216 participants
- Enrollment target
Study Summary
In the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial, the investigators propose to establish which immunosuppressive therapy, methotrexate or mycophenolate mofetil, is more effective as a first-line, corticosteroid-sparing agent for the treatment of non-infectious uveitis in a block-randomized, observer-masked, comparative effectiveness trial.
Interventions
- DRUG Prednisone
- DRUG Methotrexate
- DRUG Mycophenolate mofetil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2013-08 |
| Est. Completion | 2018-08-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01829295
The ClinicalTrials.gov registry entry for NCT01829295 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Prednisone is the first listed.
NCT01829295 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01829295 about?
NCT01829295 is a clinical study titled "Methotrexate and Mycophenolate Mofetil for UVEITIS". In the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial, the investigators propose to establish which immunosuppressive therapy, methotrexate or mycophenolate mofetil, is more effective as a first-line, corticosteroid-sparing agent for the treatment of non-infectious uvei...
What is the current status of trial NCT01829295?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 216 participants. The study started on 2013-08. Estimated completion is 2018-08-09.
What interventions are being tested in trial NCT01829295?
The interventions under investigation include: Prednisone (DRUG), Methotrexate (DRUG), Mycophenolate mofetil (DRUG).
Who is sponsoring clinical trial NCT01829295?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.